NCT03040765 - Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions

Thalassemia Majors (Beta-Thalassemia Major)Osteoporosis

Interventions

DRUG

Denosumab 60 MG/ML Prefilled Syringe

Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major

DRUG

Zoledronic Acid 5Mg/Bag 100Ml Inj

Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major

Trial Locations (1)

National Center for Cancer Care & Research (NCCCR), Doha